Zevra Therapeutics (ZVRA) Competitors $8.66 +0.05 (+0.58%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$8.65 -0.01 (-0.16%) As of 05/21/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. RXRX, TWST, TARS, GLPG, APGE, BEAM, SDGR, BHC, AGIO, and ARQTShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Recursion Pharmaceuticals (RXRX), Twist Bioscience (TWST), Tarsus Pharmaceuticals (TARS), Galapagos (GLPG), Apogee Therapeutics (APGE), Beam Therapeutics (BEAM), Schrödinger (SDGR), Bausch Health Companies (BHC), Agios Pharmaceuticals (AGIO), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Recursion Pharmaceuticals Twist Bioscience Tarsus Pharmaceuticals Galapagos Apogee Therapeutics Beam Therapeutics Schrödinger Bausch Health Companies Agios Pharmaceuticals Arcutis Biotherapeutics Recursion Pharmaceuticals (NASDAQ:RXRX) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation. Which has stronger valuation and earnings, RXRX or ZVRA? Zevra Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$59.82M27.80-$328.07M-$1.77-2.31Zevra Therapeutics$23.61M20.05-$46.05M-$1.90-4.56 Do institutionals & insiders have more ownership in RXRX or ZVRA? 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 15.8% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer RXRX or ZVRA? Recursion Pharmaceuticals presently has a consensus price target of $7.60, indicating a potential upside of 85.82%. Zevra Therapeutics has a consensus price target of $22.29, indicating a potential upside of 157.34%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has more volatility & risk, RXRX or ZVRA? Recursion Pharmaceuticals has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Does the media prefer RXRX or ZVRA? In the previous week, Zevra Therapeutics had 18 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 24 mentions for Zevra Therapeutics and 6 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 1.24 beat Zevra Therapeutics' score of 0.73 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor RXRX or ZVRA? Zevra Therapeutics received 6 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 95.00% of users gave Zevra Therapeutics an outperform vote while only 56.14% of users gave Recursion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRecursion PharmaceuticalsOutperform Votes3256.14% Underperform Votes2543.86% Zevra TherapeuticsOutperform Votes3895.00% Underperform Votes25.00% Is RXRX or ZVRA more profitable? Zevra Therapeutics has a net margin of -342.63% compared to Recursion Pharmaceuticals' net margin of -579.52%. Recursion Pharmaceuticals' return on equity of -76.56% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-579.52% -76.56% -55.68% Zevra Therapeutics -342.63%-159.54%-51.50% SummaryZevra Therapeutics beats Recursion Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$473.53M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-4.408.9226.8419.71Price / Sales20.05253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book5.066.466.794.50Net Income-$46.05M$143.98M$3.23B$248.18M7 Day Performance2.73%2.03%1.53%0.20%1 Month Performance18.47%4.11%10.06%12.37%1 Year Performance87.04%-2.87%16.72%7.04% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics3.2372 of 5 stars$8.66+0.6%$22.29+157.3%+87.4%$473.53M$23.61M-4.4020News CoverageAnalyst RevisionRXRXRecursion Pharmaceuticals2.4182 of 5 stars$4.56+7.3%$7.60+66.7%-57.0%$1.85B$59.82M-2.98400Positive NewsGap UpTWSTTwist Bioscience4.2977 of 5 stars$30.93+2.8%$50.40+62.9%-35.4%$1.85B$347.68M-9.15990Positive NewsTARSTarsus Pharmaceuticals3.2652 of 5 stars$43.70+0.5%$66.33+51.8%+14.2%$1.84B$233.67M-11.4750Positive NewsGLPGGalapagos0.4786 of 5 stars$27.75+3.3%$25.33-8.7%+2.1%$1.83B$288.19M0.001,310Positive NewsAPGEApogee Therapeutics2.1513 of 5 stars$40.620.0%$94.60+132.9%-18.3%$1.82BN/A-16.7991Positive NewsGap DownBEAMBeam Therapeutics3.1269 of 5 stars$17.89+3.7%$48.75+172.5%-30.6%$1.80B$63.58M-10.16510Positive NewsSDGRSchrödinger2.948 of 5 stars$23.58+0.9%$32.80+39.1%-6.9%$1.72B$230.49M-10.08790BHCBausch Health Companies4.1592 of 5 stars$4.68+1.6%$7.42+58.6%-31.3%$1.69B$9.73B-38.9619,900Positive NewsAGIOAgios Pharmaceuticals3.9899 of 5 stars$29.18+3.3%$56.00+91.9%-11.1%$1.69B$37.04M2.57390Positive NewsAnalyst DowngradeARQTArcutis Biotherapeutics2.7636 of 5 stars$14.11+3.5%$18.80+33.2%+45.1%$1.68B$212.82M-7.88150News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies Recursion Pharmaceuticals Alternatives Twist Bioscience Alternatives Tarsus Pharmaceuticals Alternatives Galapagos Alternatives Apogee Therapeutics Alternatives Beam Therapeutics Alternatives Schrödinger Alternatives Bausch Health Companies Alternatives Agios Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZVRA Stock Free ZVRA Stock Alerts